| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4007300 | Archivos de la Sociedad Española de Oftalmología | 2013 | 4 Pages |
Abstract
The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
S. Copete-Piqueras, C. Cava-Valenciano, I. Flores-Moreno, A. Moreno-Valladares, V. Bautista Ruescas,